Bausch Health (NYSE/TSX:BHC), formerly known as Valeant Pharmaceuticals, has agreed to pay $300 million to settle allegations that the company paid rivals to keep a generic version of Glumetza off the market. In 2015, the Laval, Canada–based company increased the drug’s price by almost eight-fold. The plaintiffs, drug distributor companies, in the class-action suit filed…